KisoJi Scientific and Clinical Advisors

KisoJi is fortunate to have scientific and clinical advisors who are at the forefront of immunology and oncology, having made key contributions to the field.

Hua Gu, Ph.D.

Scientific Advisor

Dr. Gu pioneered conditional gene targeting with Dr. Klaus Rajewsky to dissect B-cell molecular immunology in transgenic mice. Currently he is the Director, Molecular Immunology Research Unit, IRCM. André-Aisenstadt Chair of Excellence, Full Research Professor, Department of Microbiology, Infectiology and Immunology, Université de Montréal.

Read more

Marina Konopleva, M.D., Ph.D.

Scientific Advisor

Dr. Konopleva pioneered metabolic reprogramming in cancer associated with oxidative phosphorylation and glutaminase inhibition. Currently she is Chief, Section of Leukemia Biology Research, Professor, and Deputy Department Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston. She is also the Frances King Black Endowed Professor for Cancer Research, Department of Leukemia at MD Anderson.

Read more

Serge Muyldermans, Ph.D.

Scientific Advisor

Dr. Muyldermans obtained his Ph.D. at the ‘Vrije Universiteit Brussel’, Brussels, Belgium in 1982. He was a postdoc at this university at the time the functional Heavy-chain only antibodies were discovered in camelids. He developed a streamlined method to rapidly identify the antigen-specific, single-domain antibody fragments derived from the unique Heavy chain antibodies of camelids.

Read more

Adrian Sacher, M.D., M.MSc., FRCPC

Clinical Advisor

Dr. Sacher is a staff medical oncologist in the thoracic and genitourinary tumor sites at the Princess Margaret Cancer Centre and an Assistant Professor of medicine at the University of Toronto. He has previously worked at the Herbert Irving Comprehensive Cancer Center at Columbia University & New York-Presbyterian Hospital where he served as an Assistant Professor of medicine and attending medical oncologist specializing in thoracic oncology and phase I drug development.

Read more

Want to know more about us?